In Vitro Antifungal Resistance of Candida auris Isolates from Bloodstream Infections, South Africa
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Candida auris is a multidrug-resistant fungal pathogen that is endemic in South African hospitals. We tested bloodstream C. auris isolates that were submitted to a reference laboratory for national laboratory-based surveillance for candidemia in 2016 and 2017.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Surveillance studies have demonstrated that MGX was the most mycologically active agent against over 400 diverse C. auris isolates, including strains which were multi-drug resistant (19, 20).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics
White, T. J., Bruns, T., Lee, S., & Taylor, J. (1990) · PCR Protocols · doi:10.1016/b978-0-12-372180-8.50042-1 · Cited by 36,648
PCR protocols — A guide to methods and applications
U.G. (1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90252-7 · Cited by 11,702
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 9×
“Resistant (n= 84) Fluconazole 1 (8) 60 (78) 1 (50) Amphotericin B 0 1 (1) 0 Micafungin 0 0 0 Fluconazole and amphotericin B 12 (92) 7 (9) 0 Fluconazole, amphotericin B, and micafungin 0 2 (3) 0”
BackgroundResultInfluentialSelf-citationChowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577 · cited 4×
“auris isolates collected between 2009 and 2017 reported that 14% were resistant to both azoles and flucytosine, 7% to both azoles and amphotericin B, and 2% to azoles and echinocandins (2).”
BackgroundInfluentialKathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532 · cited 2×
“auris isolates are resistant to all classes of systemic antifungal agents in current use for candidemia (9, 10).”
BackgroundChow, N. A., Muñoz, J. F., Gade, L., Berkow, E., Li, X., Welsh, R. M., Forsberg, K., Lockhart, S. R., Adam, R., Alanio, A., et al. (2020) · doi:10.1101/2020.01.06.896548 · Cited by 463
Self-citationMuñoz, J. F., Gade, L., Chow, N. A., Loparev, V. N., Juieng, P., Berkow, E. L., Farrer, R. A., Litvintseva, A. P., & Cuomo, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-07779-6 · Cited by 458 · cited 4×
“Reference sequences and annotations for these genes were obtained from the susceptible clade I reference strain C. auris B8441 (GenBank accession number PEKT00000000) and the clade III C. auris B11221 isolate (GenBank accession number PGLS00000000) (1, 9).”
BackgroundInfluentialSelf-citationCandida auris : The recent emergence of a multidrug-resistant fungal pathogen
Forsberg, K., Woodworth, K., Walters, M., Berkow, E. L., Jackson, B., Chiller, T., & Vallabhaneni, S. (2019) · Medical Mycology · doi:10.1093/mmy/myy054 · Cited by 421 · cited 1×
“Antifungal resistance seems to be clade specific; clade I, III, and IV isolates may be resistant to multiple antifungal agents, while clade II isolates are generally more susceptible (13, 14).”
BackgroundAntifungal Combinations for Treatment of Cryptococcal Meningitis in Africa
Molloy, S. F., Kanyama, C., Heyderman, R. S., Loyse, A., Kouanfack, C., Chanda, D., Mfinanga, S., Temfack, E., Lakhi, S., Lesikari, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710922 · Cited by 396 · cited 1×
“A combination of amphotericin B and flucytosine is a potent regimen and is known to be efficacious for other serious fungal infections, such as cryptococcal meningitis (21).”
BackgroundMultidrug-resistant endemic clonal strain of Candida auris in India
Chowdhary, A., Anil Kumar, V., Sharma, C., Prakash, A., Agarwal, K., Babu, R., Dinesh, K. R., Karim, S., Singh, S. K., Hagen, F., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2027-1 · Cited by 373 · cited 1×
“Clade I and III echinocandin-resistant isolates have been reported to have either the S639F or S639Y substitution (7, 14).”
BackgroundAntifungal Susceptibility Testing: Current Approaches
Berkow, E. L., Lockhart, S. R., & Ostrosky-Zeichner, L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00069-19 · Cited by 368 · cited 1×
“We used the Etest method since it generates a much wider range of amphotericin B MIC values than those yielded by BMD testing; this may facilitate distinguishing resistant and susceptible isolates (38).”
MethodPotential Fifth Clade of Candida auris, Iran, 2018
Chow, N. A., de Groot, T., Badali, H., Abastabar, M., Chiller, T. M., & Meis, J. F. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2509.190686 · Cited by 356 · cited 2×
“, South Asian (clade I), East Asian (clade II), African (clade III), and South American (clade IV) (11), with a potential clade V represented by a single isolate (11).”
BackgroundFitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B
Vincent, B. M., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., & Lindquist, S. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001692 · Cited by 322 · cited 1×
“Amphotericin B resistance is not commonly described among Candida species (11, 26).”
BackgroundMechanisms of echinocandin antifungal drug resistance
Perlin, D. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12831 · Cited by 313 · cited 1×
“auris, echinocandin resistance is associated with mutations in the hot spot regions of the FKS genes (FKS1, FKS2, and FKS3), which encode b-1,3-D-glucan synthase (32).”
BackgroundArendrup, M. C., Prakash, A., Meletiadis, J., Sharma, C., & Chowdhary, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00485-17 · Cited by 270
Candida auris–Associated Candidemia, South Africa
Magobo, R. E., Corcoran, C., Seetharam, S., & Govender, N. P. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.131765 · Cited by 259
Self-citationUnderstanding Echinocandin Resistance in the Emerging Pathogen Candida auris
Kordalewska, M., Lee, A., Park, S., Berrio, I., Chowdhary, A., Zhao, Y., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00238-18 · Cited by 247 · cited 1×
“In addition, S639F/S639P mutations in the FKS1 hot spot 1 region have been detected in echinocandin-resistant isolates (14, 15).”
BackgroundGenomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris
Rhodes, J., Abdolrasouli, A., Farrer, R. A., Cuomo, C. A., Aanensen, D. M., Armstrong-James, D., Fisher, M. C., & Schelenz, S. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0045-x · Cited by 246 · cited 2×
“In a large clade I C. auris outbreak involving 72 patients in the United Kingdom, Rhodes et al. reported 5 amphotericin B-resistant isolates with MICs of 2mg/ml, none of which had any ERG3, ERG5, or ERG6mutations (28).”
BackgroundEscandón, P., Chow, N. A., Caceres, D. H., Gade, L., Berkow, E. L., Armstrong, P., Rivera, S., Misas, E., Duarte, C., Moulton-Meissner, H., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy411 · Cited by 222
Espinel-Ingroff, A., Arendrup, M. C., Pfaller, M. A., Bonfietti, L. X., Bustamante, B., Canton, E., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Fothergill, A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01519-13 · Cited by 216
Sharma, C., Kumar, N., Pandey, R., Meis, J. F., & Chowdhary, A. (2016) · New Microbes and New Infections · doi:10.1016/j.nmni.2016.07.003 · Cited by 202 · cited 1×
“Resistant (n= 84) Fluconazole 1 (8) 60 (78) 1 (50) Amphotericin B 0 1 (1) 0 Micafungin 0 0 0 Fluconazole and amphotericin B 12 (92) 7 (9) 0 Fluconazole, amphotericin B, and micafungin 0 2 (3) 0”
Mutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris
Rybak, J. M., Muñoz, J. F., Barker, K. S., Parker, J. E., Esquivel, B. D., Berkow, E. L., Lockhart, S. R., Gade, L., Palmer, G. E., White, T. C., et al. (2020) · mBio · doi:10.1128/mbio.00365-20 · Cited by 202 · cited 5×
“reported 16 clade IV isolates harboring A651T TAC1b substitutions (16).”
BackgroundResultInfluentialSelf-citationIdentification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans
Martel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Rolley, N., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00348-10 · Cited by 168
Healey, K. R., Kordalewska, M., Jiménez Ortigosa, C., Singh, A., Berrío, I., Chowdhary, A., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01427-18 · Cited by 165 · cited 1×
“contrast, a very low prevalence of fluconazole resistance has been reported for clade IV Colombian isolates and clade II Japanese isolates (2, 22, 23).”
BackgroundCombined Antifungal Resistance and Biofilm Tolerance: the Global Threat of Candida auris
Kean, R., & Ramage, G. (2019) · mSphere · doi:10.1128/msphere.00458-19 · Cited by 152
Epidemiologic Shift in Candidemia Driven by Candida auris, South Africa, 2016–20171
van Schalkwyk, E., Mpembe, R. S., Thomas, J., Shuping, L., Ismail, H., Lowman, W., Karstaedt, A. S., Chibabhai, V., Wadula, J., Avenant, T., et al. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2509.190040 · Cited by 137
Self-citationNiimi, K., Maki, K., Ikeda, F., Holmes, A. R., Lamping, E., Niimi, M., Monk, B. C., & Cannon, R. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1148-1155.2006 · Cited by 134 · cited 1×
“affected by multidrug transporters (31).”
Clade-specific chromosomal rearrangements and loss of subtelomeric adhesins in Candida auris
Muñoz, J. F., Welsh, R. M., Shea, T., Batra, D., Gade, L., Howard, D., Rowe, L. A., Meis, J. F., Litvintseva, A. P., & Cuomo, C. A. (2021) · Genetics · doi:10.1093/genetics/iyab029 · Cited by 125 · cited 1×
“MRR1mutations have been noted only in clade III isolates (16, 25).”
BackgroundSelf-citationIdentification of Drug Resistant Candida auris
Kordalewska, M., & Perlin, D. S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01918 · Cited by 124 · cited 1×
“auris infections reported worldwide is of major concern because this fungus is difficult to identify using standard identification methods, is often multidrug resistant, and can cause large outbreaks in acute hospital and long-term health care settings (9, 20).”
BackgroundKhan, Z., Ahmad, S., Al-Sweih, N., Joseph, L., Alfouzan, W., & Asadzadeh, M. (2018) · PLOS ONE · doi:10.1371/journal.pone.0195743 · Cited by 109 · cited 1×
“The Etest method yields a much wider MIC range, compared to BMD, partly because the strip includes lower antifungal concentrations (27).”
MethodCandida auris in South Africa, 2012–2016
Govender, N. P., Magobo, R. E., Mpembe, R., Mhlanga, M., Matlapeng, P., Corcoran, C., Govind, C., Lowman, W., Senekal, M., & Thomas, J. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2411.18-0368 · Cited by 96 · cited 1×
“auriswas first detected in South Africa in 2009, health care-associated transmission events and large outbreaks have led to this pathogen accounting for more than 1 in 10 cases of candidemia (3, 17, 18).”
BackgroundSelf-citationWelsh, R. M., Sexton, D. J., Forsberg, K., Vallabhaneni, S., & Litvintseva, A. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.00007-19 · Cited by 90 · cited 1×
“Differences in genetic backgrounds, biochemical characteristics, and antifungal susceptibility patterns make each clade unique (12).”
BackgroundBing, J., Hu, T., Zheng, Q., Muñoz, J. F., Cuomo, C. A., & Huang, G. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01466-20 · Cited by 86 · cited 3×
“functions as a lanosterol 14,a-demethylase of the cytochrome P450 family (24).”
BackgroundInfluentialSelf-citationBranco, J., Ola, M., Silva, R. M., Fonseca, E. S. S., Gomes, N. C., Martins-Cruz, C., Silva, A. P., Silva-Dias, A., Pina‐Vaz, C., Erraught, C., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.02.002 · Cited by 75 · cited 1×
“results in azole resistance in some clinical isolates of Candida albicans and Candida parapsilosis (29, 30).”
BackgroundPfaller, M. A., Messer, S. A., Diekema, D. J., Jones, R. N., & Castanheira, M. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02481-13 · Cited by 74
Pfaller, M. A., Diekema, D. J., Jones, R. N., & Castanheira, M. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.00782-14 · Cited by 51 · cited 1×
“Caspofungin MICs were not categorized due to the previously reported interlaboratory MIC variability noted for Candida species as a result of batch-to-batch variations in the powder’s potency (36, 37).”
BackgroundGovender, N. P., Avenant, T., Brink, A. J., Chibabhai, V., Cleghorn, J., du Toit, B., Govind, C., Lewis, E., Lowman, W., Mahlangu, H., et al. (2019) · Southern African Journal of Infectious Diseases · doi:10.4102/sajid.v34i1.163 · Cited by 46 · cited 2×
“auris infection and amphotericin B as an alternative agent in clinical settings where echinocandins are unavailable (6).”
BackgroundSelf-citationMultilocus sequence typing of azole-resistant Candida auris strains, South Africa
Magobo, R. E., Mhlanga, M., Corcoran, C., & Govender, N. P. (2020) · Southern African Journal of Infectious Diseases · doi:10.4102/sajid.v35i1.116 · Cited by 22 · cited 1×
“However, our study sample was derived from 2-year national surveillance of candidemia and provides a much more representative picture of the antifungal susceptibility profile (19).”
MethodSelf-citation
Research works printed but not linked: 1
- Clinical and Laboratory Standard Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
Cited by
Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents
Jacobs, S. E., Jacobs, J. L., Dennis, E. K., Taimur, S., Rana, M., Patel, D., Gitman, M., Patel, G., Schaefer, S., Iyer, K., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00053-22 · Cited by 190
Rybak, J. M., Barker, K. S., Muñoz, J. F., Parker, J. E., Ahmad, S., Mokaddas, E., Abdullah, A., Elhagracy, R. S., Kelly, S. L., Cuomo, C. A., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.024 · Cited by 120
Self-citationVazquez, J. A., Pappas, P. G., Boffard, K., Paruk, F., Bien, P. A., Tawadrous, M., Ople, E., Wedel, P., Oborska, I., & Hodges, M. R. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01419-22 · Cited by 92
Burrack, L. S., Todd, R. T., Soisangwan, N., Wiederhold, N. P., & Selmecki, A. (2022) · mBio · doi:10.1128/mbio.00842-22 · Cited by 82
Strategies to Prevent Transmission of Candida auris in Healthcare Settings
Ahmad, S., & Asadzadeh, M. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00451-7 · Cited by 77
Metadata
- Authors
- Maphanga, T. G., Naicker, S. D., Kwenda, S., Muñoz, J. F., van Schalkwyk, E., Wadula, J., Nana, T., Ismail, A., Coetzee, J., Govind, C., Mtshali, P. S., Mpembe, R. S., & Govender, N. P.
- Affiliations
- National Health Laboratory Service (ZA)
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
- National Institute for Communicable Diseases, Centre for Healthcare-Associated Infections, Antimicrobial Resistance, and Mycoses, National Health Laboratory Service, Johannesburg, South Africa
- AMPATH National Laboratory Service, Centurion, South Africa
- Lancet Laboratories (ZA)
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2021-08-17
- Volume
- 65
- Issue
- 9
- Pages
- e0051721-e0051721
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC8370198
- OpenAlex
- W3178182121
- Cited by
- 78
- References
- 38
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 19 · 2023: 12 · 2022: 15 · 2021: 4
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- doi.org/10.1128/ASMCopyrightv2 (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida auris, antifungal resistance, bloodstream infection, azole resistance, polyene resistance, echinocandin resistance, resistance gene mutations, in vitro susceptibility, South Africa
- MeSH terms
- Antifungal Agents, Candida, Humans, Microbial Sensitivity Tests, South Africa, Fluconazole, Drug Resistance, Fungal, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.